They have a greater breadth of the spectrum ...

They have a greater breadth of the spectrum of psychotropic action with fewer side effects. Nuclear options melancholy of endogenous depression with typical symptoms tsirkadnovitalnoy, severe (psychotic) depression and depressivnobredovye condition worse respond to therapy with SSRIs. In contrast, depression with obessivnofobicheskoy, hypochondriacal and anxious symptoms of neurotic level are treated quite successfully. These patients are often observed sonbodrstvovanie cycle disorders (difficulty falling asleep, sleepiness during the day), while in remission residual depressive symptoms (often distimicheskogo character). In addition to depression with atypical symptoms, was shown the high efficiency of serotonergic antidepressants in anxiety disorders and obessivnokompulsivnyh alone or comorbid with depression, as well as panic disorder, postravmaticheskom stress disorder, social phobia, somatoform disorders and other anxiety disorders. It is not excluded that the basis of all these violations are kakieto general pathogenetic pattern is likely related to the failure of central serotonergic structures. Scientific development of the latest generation of antidepressants, on the one hand, it goes in the direction of increasing the specificity of their biochemical actions. In particular, synthesized and tested selective agonists and antagonists of monoamine neuroreceptors. So, found a substance that selectively affect 5NT1, 5NT2 and 5NT3 serotonin receptors. Examples include direct serotonin receptor agonists 5NT1a (flezinoksan, ipsapiron, etc.) or a direct impact on them mirtazapine. On the other hand, the trend in the development of a wide variety of biochemical action on the monoamine systems with minimal impact on the receptors with which the development of side effects (eg, milnacipran, venlafaxine, nefazodone, mirtazapine, duloxetine, etc.). Finally, the mechanism of action of some drugs with timoanalepticheskoy activity not directly related to the monoamine system, or is insufficiently clear (eg, tianeptine, alprazolam, Sadenozilmetionin, neuropeptides, etc.). An important objective of the present stage of pharmacotherapy of mental illness is a secondary prevention of relapses of affective and schizoaffective structure at faznoprotekayuschih psychoses, especially bipolar disorder, as it is about overcoming some of the negative trends in drug pathomorphism mental illness and retaining a high level of social adaptation in the most intact part of the patients with endogenous psychoses. In this regard, the discovery of lithium salts normotimicheskih properties was a major breakthrough in the biological therapy of endogenous psychoses. However, it appeared that 20 to 50% of patients, according to different authors, are resistant to prophylactic therapy with lithium. This is especially true of patients with a continual nature of affective disorders, in particular, farmakogennym swaying circular disturbances due to unreasonably massive use of tricyclic antidepressants, withdrawal of psychotropic drugs, etc.